Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Small Molecule Kinase Inhibitors market. World market for small molecule kinase inhibitor drugs is projected to reach $16.2 billion by the year 2015. This is primarily driven by the rising interest over the potential of kinase inhibitors in effectively blocking, and modifying protein kinase triggered tumor cell metabolism, proliferation, and DNA damage. Strong growth in the future will be led by expansion of treatment indications in both oncology, and non-oncology disease areas.

San Jose, CA (PRWEB) June 30, 2009 -- With over 500 identified types of kinase proteins in the human body, its little surprise that these enzymes continue to remain important drug targets for major pharmaceutical drug developers, especially in the oncology space. Given their role in effectively disrupting cell signal pathways, kinase inhibitors are of special interest in the treatment of cancer. The unprecedented success witnessed in patient outcomes with the use of currently commercialized kinase inhibitors, such as, imatinib, among others, has ignited excitement over the untapped potential of this very potent class of drugs. Rising incidences of cancer, and the yet unmet treatment needs offer a strong business case for kinase inhibitors.

The upcoming years are forecast to witness both the strong growth for multi-targeted kinase inhibitors, and the rising popularity of combination drug therapies. Growing incidences of tumor cell resistance to single targeted kinase inhibitor drugs is fingered as the key reason triggering interest in both combination drug therapies, and multi-targeted kinase inhibitors. For instance, growing incidences of resistance to Gleevec, has turned the spotlight on Nexavar, and Sutent, given the potential of these new drugs to offer the much awaited solution to the treatment impasse hitherto encountered. The multi-targeted kinase inhibitors market (http://www.strategyr.com/Small_Molecule_Kinase_Inhibitors_Market_Report.asp) is expected to benefit from the growing acceptance of the undisputable fact that the battle against cancer can be horned not by blocking out tumor cells at one point, but by simultaneously blocking multiple biological triggers and pathways, given the tendency of these cells to regroup to recalibrate and spread through new growth paths.

Global sales of Gleevec (http://www.strategyr.com/Small_Molecule_Kinase_Inhibitors_Market_Report.asp) are projected to steadily increase between the period 2010 and 2015, as stated by the new market research report. New generation kinase inhibitor drugs like Nexavar (http://www.strategyr.com/Small_Molecule_Kinase_Inhibitors_Market_Report.asp) are forecast to witness robust growth over the period 2006 through 2015.

Leading players operating in the marketplace include Amgen Inc, Novartis, AstraZeneca plc, Genentech, Roche, OSI Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Glaxo SmithKline, Wyeth, Onyx Pharmaceuticals Inc., Merck & Co. Inc, KAI Pharmaceuticals Inc, Celgene Corporation, Sanofi-Aventis, and Bayer Schering Pharma AG, among others.

The report titled "Small Molecule Kinase Inhibitors: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of industry overview, technology, trends, growth drivers, challenges, and most promising drugs in pipeline. Also provided are profiles of major players, and an enumeration of recent developments, mergers, acquisitions, and other strategic industry activities. Global small molecule kinase inhibitors market is analyzed by sales in US$ billion of major drug brands, such as, Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, and Tykerb/Tyverb, among others.

For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Small_Molecule_Kinase_Inhibitors_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) (http://www.strategyR.com/) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press (at) StrategyR (dot) com

Web Site http://www.StrategyR.com/

###